Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Jpn J Ophthalmol ; 68(3): 211-215, 2024 May.
Article in English | MEDLINE | ID: mdl-38609716

ABSTRACT

PURPOSE: To investigate the association between the arm-to-choroidal circulation time (ACT) on indocyanine green angiography (IA) and clinical profile in patients with polypoidal choroidal vasculopathy (PCV). STUDY DESIGN: Single-center retrospective study. METHODS: We included 38 eyes of 38 patients with PCV diagnosed using multimodal imaging and did not undergo previous treatment. All patients were treated with monthly aflibercept injections for 3 months and treat-and-extend regimens for the subsequent 12 months. Posterior vortex vein ACT was assessed on the first visit using Heidelberg IA. The patients were divided into two groups: ACT ≥20 s (L group; eight eyes) and ACT <20 s (S group; 30 eyes). The clinical profiles before and after treatment were analyzed to assess associations with ACT. RESULTS: The mean ACT was 16.39±3.3 s (L group: 21.25±1.49 s, women:men=2:6, mean age: 77.3±6.5 years; S group: 15.10±2.17 s, women:men=7:23, mean age: 75.5±6.9 years). No significant difference was observed in the mean subfoveal choroidal thickness between the L and the S groups (176±75 µm vs. 230±79 µm, P=0.10). However, there were significant differences between the L and S groups in retinal fluid accumulation and hemorrhage recurrence (eight/eight eyes, 100% vs. 13/30 eyes, 43%, P<0.001), mean aflibercept injections (8.8±1.6 vs. 7.0±1.6, P<0.01) during the 12-month period, and the number of polypoidal lesions (1.8±0.7 vs. 1.3±0.5, P<0.05). CONCLUSION: Patients with PCV and ACT >20 s are more likely to experience exudative change recurrence in the retina during treatment because they have more polypoidal lesions.


Subject(s)
Choroid , Fundus Oculi , Polypoidal Choroidal Vasculopathy , Polyps , Receptors, Vascular Endothelial Growth Factor , Aged , Aged, 80 and over , Female , Humans , Male , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/therapeutic use , Blood Flow Velocity/physiology , Choroid/blood supply , Choroid/diagnostic imaging , Coloring Agents/administration & dosage , Fluorescein Angiography/methods , Follow-Up Studies , Indocyanine Green/administration & dosage , Intravitreal Injections , Multimodal Imaging , Polypoidal Choroidal Vasculopathy/diagnosis , Polypoidal Choroidal Vasculopathy/drug therapy , Polyps/diagnosis , Polyps/drug therapy , Polyps/physiopathology , Receptors, Vascular Endothelial Growth Factor/therapeutic use , Receptors, Vascular Endothelial Growth Factor/administration & dosage , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/therapeutic use , Regional Blood Flow/physiology , Retrospective Studies , Tomography, Optical Coherence/methods , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL